Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- RXRX
- Price
- 3.46
- Stock movement up
- +0.26 (5.58%)
- Company name
- Recursion Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.53B
- Ent value
- 2.23B
- Price/Sales
- 38.86
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -35.09%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RXRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 38.86 |
| Price to Book | - |
| EV to Sales | 34.15 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 514.90M |
| EPS (TTM) | -1.22 |
| FCF per share (TTM) | -0.72 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 74.56M |
| Gross profit (TTM) | -23.90M |
| Operating income (TTM) | -648.13M |
| Net income (TTM) | -644.76M |
| EPS (TTM) | -1.22 |
| EPS (1y forward) | -0.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -32.05% |
| Operating margin (TTM) | -869.26% |
| Profit margin (TTM) | -864.74% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 743.29M |
| Net receivables | 24.65M |
| Total current assets | 812.85M |
| Goodwill | 162.16M |
| Intangible assets | 309.90M |
| Property, plant and equipment | 0.00 |
| Total assets | 1.47B |
| Accounts payable | 18.12M |
| Short/Current long term debt | 77.97M |
| Total current liabilities | 147.71M |
| Total liabilities | 343.26M |
| Shareholder's equity | 1.13B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -371.81M |
| Capital expenditures (TTM) | 6.47M |
| Free cash flow (TTM) | -378.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -57.01% |
| Return on Assets | -43.74% |
| Return on Invested Capital | -55.94% |
| Cash Return on Invested Capital | -32.82% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.63 |
| Daily high | 4.94 |
| Daily low | 4.58 |
| Daily Volume | 19.7M |
| All-time high | 41.33 |
| 1y analyst estimate | 6.71 |
| Beta | 0.96 |
| EPS (TTM) | -1.22 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| RXRX | S&P500 | |
| Current price drop from All-time high | -91.63% | -1.82% |
| Highest price drop | -90.68% | -56.47% |
| Date of highest drop | 20 Nov 2025 | 9 Mar 2009 |
| Avg drop from high | -85.74% | -10.84% |
| Avg time to new high | - | 12 days |
| Max time to new high | 290 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.53B
Marketcap category
Mid-cap
Description
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Employees
600
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page